MDT

89.61

+0.86%↑

VEEV

280.74

-0.17%↓

113.6

-0.53%↓

WBA

11.51

0%↓

HQY

97.6

+0.13%↑

MDT

89.61

+0.86%↑

VEEV

280.74

-0.17%↓

113.6

-0.53%↓

WBA

11.51

0%↓

HQY

97.6

+0.13%↑

MDT

89.61

+0.86%↑

VEEV

280.74

-0.17%↓

113.6

-0.53%↓

WBA

11.51

0%↓

HQY

97.6

+0.13%↑

MDT

89.61

+0.86%↑

VEEV

280.74

-0.17%↓

113.6

-0.53%↓

WBA

11.51

0%↓

HQY

97.6

+0.13%↑

MDT

89.61

+0.86%↑

VEEV

280.74

-0.17%↓

113.6

-0.53%↓

WBA

11.51

0%↓

HQY

97.6

+0.13%↑

Начало・Списък с акции・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Отворен

СекторЗдравеопазване

6.55 -1.21

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.51

Максимум

6.73

Ключови измерители
By Trading Economics
Приходи	30M -36M
Продажби	1.6M 31M
Марж на печалбата	-117.018
Служители	181
EBITDA	24M -40M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+306.06% upside

Дивиденти
By Dow Jones
Следващи печалби	29.07.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-132M 672M
Предишно отваряне	7.76
Предишно затваряне	6.55

Настроения в новините

By Acuity

50%

154 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

6.26 / 7.47 Подкрепа & съпротива

Day One Biopharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.07.2025 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15.07.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15.07.2025 г., 23:05 ч. UTC

Пазарно говорене

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15.07.2025 г., 21:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.07.2025 г., 21:36 ч. UTC

Пазарно говорене

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

15.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

15.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

15.07.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15.07.2025 г., 20:07 ч. UTC

Печалби

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15.07.2025 г., 20:06 ч. UTC

Пазарно говорене

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15.07.2025 г., 19:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

15.07.2025 г., 19:54 ч. UTC

Пазарно говорене

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15.07.2025 г., 19:38 ч. UTC

Пазарно говорене

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15.07.2025 г., 19:09 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15.07.2025 г., 19:07 ч. UTC

Пазарно говорене

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15.07.2025 г., 19:03 ч. UTC

Пазарно говорене

Gold Slips as Big Buyers Pull Back -- Market Talk

15.07.2025 г., 18:32 ч. UTC

Придобивния, сливания и поглъщания

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15.07.2025 г., 18:31 ч. UTC

Придобивния, сливания и поглъщания

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15.07.2025 г., 18:13 ч. UTC

Пазарно говорене

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15.07.2025 г., 17:40 ч. UTC

Пазарно говорене

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15.07.2025 г., 17:40 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.07.2025 г., 17:25 ч. UTC

Придобивния, сливания и поглъщания

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15.07.2025 г., 17:24 ч. UTC

Пазарно говорене

Dollar Gains Strength After Inflation Data -- Market Talk

15.07.2025 г., 16:49 ч. UTC

Пазарно говорене

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

15.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

15.07.2025 г., 15:42 ч. UTC

Пазарно говорене

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Day One Biopharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

306.06% нагоре

12-месечна прогноза

Среден 28.14 USD 306.06%

Висок 36 USD

Нисък 20 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Day One Biopharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Day One Biopharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

6.26 / 7.47Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Настроение

By Acuity

154 / 376 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.